Table 3. Efficacy results: PFS and OS (intention-to-treat analysis).
| RT-5-FU (n=30) | RT-GC (n=32) | RT-GC+GC (n=31) | |
|---|---|---|---|
| Median PFS (months) | 4.0 | 5.6 | 6.0 |
| 95% CI | 3.5–6.2 | 4.4–8.5 | 4.8–11.9 |
| Median OS (months) | 9.6 | 9.3 | 7.3 |
| 95% CI | 8.5–11.1 | 7.3–12.2 | 5.3–15.2 |
| 9-month OS rate (%) | 58 | 52 | 45 |
| 95% CI | 43–80 | 37–74 | 31–67 |
| 18-month OS rate (%) | 11 | 11 | 22 |
| 95% CI | 4–32 | 4–31 | 11–43 |
Abbreviations: 5-FU=5-fluorouracil; C=cisplatin; CI=confidence interval; G=gemcitabine; OS=overall survival; PFS=progression-free survival; RT=radiotherapy.